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Background: The data comparing daily versus intermittent iron supplementation during 
pregnancy remain controversial. This study was undertaken to compare the efficacy of daily 
versus two different intermittent iron supplementation regimes on hematologic markers and 
birth outcomes in nonanemic pregnant women.
Methods: Two hundred and ten women with singleton pregnancies, no known disease, and 
hemoglobin levels .11.0 g/dL were randomly assigned to one of three groups, ie, Group A 
  consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), 
Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, 
  consuming one tablet daily (50 mg iron per day, n = 70). No additional micronutrients were sup-
plied.   Hemoglobin and serum ferritin levels were measured at 20, 28, and 38 weeks.   Pregnancy 
and birth outcomes (pregnancy termination, method of delivery, birth weight, stillbirth) were 
analyzed.
Results: In total, 201 women completed the protocol. There was a significant difference in mean 
hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) 
but this difference was not clinically significant (hemoglobin .12 g/dL, ferritin .19 µg/L). 
There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks. No significant 
difference was observed with respect to pregnancy or birth outcome across the groups. All 
regimens prevented the occurrence of hemoglobin ,10.5 g/dL, but weekly supplementation 
was associated with development of a hemoglobin level ,11.0 g/dL (risk ratio 0.044).
Conclusion: Twice-weekly supplementation is as effective as daily supplementation, and may 
represent an acceptable compromise in iron supplementation regimens for nonanemic pregnant 
women.
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Introduction
Iron deficiency is considered to be the most prevalent nutrient deficiency in the world, 
and iron deficiency anemia is estimated to affect 1–2 billion people globally.1 Groups 
demonstrating the highest prevalence of iron deficiency anemia are infants, children, 
and pregnant women.2 More than 50% of pregnant women in developing countries3 
and approximately 20% in industrialized countries4 suffer from iron deficiency.
During pregnancy, iron is a critical element for both the pregnant mother and the 
growing fetus,5 and is essential to neurotransmitter synthesis and myelination of the 
central nervous system. Iron also functions as a cofactor for enzymes involved in brain 
development.6 Fetal iron supply is provided by deflection of a significant proportion 
of maternal iron to the developing fetus.7Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Despite some controversy, anemia in pregnancy has 
been linked with preterm delivery and low birth weight,8 
and maternal iron deficiency in pregnancy has been linked 
with altered neurocognitive development of the infant.3 Thus, 
determination of the potentially most effective approach 
towards prevention and accurate management of anemia 
in pregnancy represents a clinical problem with global 
impact.
Although the World Health Organization (WHO) 
published recommendations on the design of large-scale 
iron supplementation programs in 19899 to alleviate this 
nutritional disease, iron supplementation during pregnancy 
remains a controversial issue. The ultimate goal of provid-
ing iron supplementation to a healthy, nonanemic pregnant 
woman is to ensure sufficient iron storage in her body to 
provide effective cover for the increased physiologic need 
of iron during pregnancy, because the natural mechanisms 
of increasing iron intake, such as higher absorption of iron 
from the gastrointestinal tract, are not always adequate. 
Women with iron deficiency are particularly susceptible to 
iron deficiency anemia during pregnancy, because the demand 
for iron increases from 0.8 to #7.5 mg of absorbed iron per 
day.10 Latent or overt iron deficiency will gradually progress 
to iron deficiency anemia, characterized by microcytosis and 
increased amounts of protoporphyrin IX in red blood cells,4 
which is linked with a risk of an unfavorable pregnancy 
outcome, as mentioned previously.
In the Islamic Republic of Iran, the prevalence of iron 
deficiency anemia in pregnant women varies between 2.4% 
and 27.8% with respect to specific regions,11 and thus repre-
sents a severe public health issue. The current policy of the 
Iranian Ministry of Health is to examine pregnant women 
for anemia at 12–17 weeks’ gestation and to supply 30 mg/
day of iron as ferrous sulfate to each pregnant woman from 
gestational week 20 until three months after delivery.11
However, discussion regarding the true desirability of 
daily iron supplements versus intermittent iron supple-
ments has arisen in recent years. The reasons for initial 
consideration of other than daily iron supplementation 
regimens are based on the lack of effectiveness of daily 
iron intervention in developing countries,12 indicated by low 
compliance with many daily supplementation programs,12 
insufficient supply of iron,11 and insufficient coverage of 
at-risk populations.12 More evidence-based theory behind 
intermittent iron supplementation reflects the original con-
cept of mucosal block of iron absorption due to an increase 
in the proportion of iron that is stored in the enterocyte, and 
a decrease in transfer of iron to transferrin in the vascular 
pool,13 confirmed decades later to some extent by in vivo 
studies in rats showing a rapid decline in the absorptive and 
iron retention capacities   during daily iron administration 
compared with an intermittent regimen. Hence, daily iron 
supplementation may not be the most efficient approach 
towards maintaining or improving the iron status of a 
woman during pregnancy.14,15
This paper reports a randomized, unsupervised field 
study designed to evaluate the relative effectiveness of once-
weekly, twice-weekly, and daily antenatal iron supplemen-
tation for maintaining safe hemoglobin and serum ferritin 
(indicator of iron reserves) levels during pregnancy and at 
delivery.
Subjects and methods
The study was conducted in North-West Iran in the urban 
regions of Urmia city. The study population was randomly 
drawn from pregnant women attending local public health 
care centers at seven prenatal health care clinics between 
September, 2007 and February, 2009. Thirty women were 
finally enrolled at each participating clinic. The women 
were invited to participate in the study during their first 
visit to the government antenatal clinic at 17–20 weeks and 
were informed by an assigned health care provider of its 
purpose, the procedures and tests entailed, and what data 
would be collected for analysis. Participants were free to 
withdraw from the study at any time without any disadvan-
tage to themselves. Written informed consent was obtained 
from each literate woman and an improvised linear shaped 
signature in front of a witness was obtained on behalf of 
illiterate women who agreed to participate in the study. 
Before the start of the study, its protocol was approved 
by the   University Ethics Committee and by the Faculty of 
Medicine. The protocol required participants to take the 
supplements on an assigned basis, to fill out forms about 
pill-taking and return these at each return clinic visit, and 
to have a 5 mL venipuncture for hemoglobin and ferritin 
concentration at 20, 28, and 38 weeks’ gestation. Women 
with previously demonstrated low hemoglobin levels or overt 
anemia were not eligible to participate. Exclusion criteria 
were hemoglobin ,11 g/dL, noncompliance, intolerance 
of iron tablets or a physician’s recommendation to refrain 
from iron intake, previous consumption of iron-containing 
supplements, multiple pregnancy, thalassemia, chronic 
systemic disease, eclampsia or pre-eclampsia, more than 
five previous completed pregnancies, history of bleeding or 
surgery during previous pregnancy, pregnancy terminated 
before 36 weeks, and relocation to another area.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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sample size, allocation of group,  
and tablet intake
A total of 210 nonanemic pregnant women with a hemoglo-
bin level .11.0 g/dL, set as a cutoff value for anemia based 
on the WHO definition,16 were recruited at .17 and ,20 
weeks of gestation for participation in this study. The 
power of the study was 80%, and the level of significance 
was considered to be P , 0.05. The prevalence of anemia 
at delivery in the daily control group versus weekly group 
was reported to be 9% versus 45%, respectively, according 
to a literature review. The women were randomly assigned 
to receive two iron tablets once weekly (100 mg/dose, 
Group A), one tablet twice weekly (50 mg/dose, Group B), 
or once daily (50 mg/day) as ferrous sulfate. The weekly 
supplemented group received two 50 mg ferrous sulfate 
tablets on Friday, and the twice-weekly supplemented group 
received one 50 mg ferrous sulfate tablet on Monday and 
Wednesday. Therefore, both groups received the same total 
amount of elemental iron per week, ie, 100 mg. All women 
were instructed to take the tablets on an empty stomach 
before sleep.
Subsequently, at 28 weeks’ gestation, four women were 
excluded due to hemoglobin ,11 g/dL, lack of compli-
ance (n = 2, Groups A and B) or relocation to another area 
(n = 2, Group A). Two hundred and six women continued 
to   participate in the study beyond 28 weeks. Data for the 
excluded women were not included in the final analysis.
At 38 weeks, three women from Group A were excluded 
due to hemoglobin levels ,11 g/dL and two women decided 
of their own volition to transfer to a daily supplementation 
regimen based on the recommendation of their private phy-
sician, in spite of having safe hemoglobin levels (12.8 g/dL 
and 11.7 g/dL). Two hundred and one women completed 
the study protocol and their data were analyzed. The study 
outline is summarized in Figure 1.
Data on age, body weight, parity, and height were 
recorded at the time of study enrolment (Table 1). Body 
mass index was calculated according to the standard for-
mula as weight in kilograms divided by the square of height 
in meters, and weight gain was assessed by the difference 
in weight at 20 and 38 weeks’ gestation. Parity was deter-
mined by self-reporting and calculated as the number of 
deliveries assigned to a particular group divided by total 
number of completed pregnancies reported by women in 
the group.
serum ferritin and hemoglobin levels
Participants were sent to a reference laboratory at assigned 
weeks of gestation according to the protocol to provide venous 
blood samples for assessment of hemoglobin and serum 
210 women recruited
and randomized
A: 70 assigned to
receive 100 mg Fe
weekly
B: 70 assigned to
receive 50 mg Fe 2x
weekly
1 woman excluded
due to incompliance
C: 70 assigned to 
receive 50 mg Fe daily
3 women excluded
(translocation n = 2,
incompliance n = 1)
5 women excluded
(HB <11 g/dL, n = 3,
recommendation, n = 2)
C: 70 women
C: 70 women
A: 67 women
B: 69 women
A: 62 women
201 women completed
the study
B: 69 women
Figure 1 Overview of clinical study.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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  ferritin concentrations. Women with hemoglobin , 11 g/dL 
at or after 28 weeks’ gestation (n = 3, Group A) were excluded 
from the study and referred to a physician to be treated with 
daily supplementation of two 50 mg ferrous sulfate tablets 
until the end of their pregnancy, and this supplementation 
regimen was continued for three months after delivery. The 
remaining participants were followed until delivery and a 
blood sample was obtained according to the protocol at 38 
weeks’ gestation. After delivery, data on infant outcome 
(birth weight and gestational age) were collected from the 
family medical file at the local health center and analyzed. 
Venous blood samples of 5 mL obtained at 20, 28, and 38 
weeks’ gestation were analyzed for hemoglobin level by the 
antenatal clinic reference laboratory using an H1 automated 
counter (Technicon, Bayer, Tehran, Iran). At these times, 
a second tube of venous blood was collected for measure-
ment of serum ferritin concentration and kept refrigerated 
until analysis. Samples for that assessment were analysed 
in the same laboratory using an immunoradiometric assay 
technique (Kavoshyar Ferritin IRMA [I125] kit, Kavoshyar 
Iran Co, Tehran, Iran).
Adherence to regimen and side effects
Overall adherence to the regime was calculated as the number 
of tablets women swallowed according to given forms, divided 
by the total number of tablets they should have received during 
supplementation, ie, number of weeks enrolled in the program 
multiplied by the number of tablets received in each group. 
Side effects were recorded at regular visits.
Medical record extraction
Birth weight and date of delivery were extracted by health 
care providers from the family file using standardized data 
entry forms for all women who completed the study protocol 
and who delivered at the local medical center at Koversusar 
Hospital, Urmia. Each women who delivers in a government 
center is given a form which she brings to the hospital and 
fills out after the birth before being discharged, which is then 
maintained in a family file.
Birth outcomes
Low birth weight was defined as ,2500 g. Gestational age 
was determined either on the basis of a participant-reported 
estimate of the last menstrual period or by an ultrasound 
examination performed early in the pregnancy. Determina-
tion of preterm birth was based solely on duration of gesta-
tion, with deliveries that occurred at ,37 completed weeks 
designated as preterm. Deliveries via cesarean section and 
stillbirths were noted.
statistical analysis
An analysis of variance test was used to assess baseline 
characteristics across the groups. We conducted analyses on 
outcomes based on randomization of the study participants 
and compared the average measurements at the designated 
time points by randomization group. Kruskal-Wallis nonpara-
metric analysis of variance was used for comparison of mean 
ferritin and hemoglobin levels across the groups. Unpaired 
t-tests were used to compare continuous outcomes between 
the randomization groups, and Chi-squared tests and post 
hoc tests, where appropriate, were used to compare differ-
ences in categorical outcomes. Risk ratios and 95% confi-
dence intervals were estimated for comparisons between the 
supplementation groups for the outcomes of preterm delivery. 
Statistical significance was set at P , 0.05. The Statistical 
Package for Social Sciences for Windows version 16.0 (SPSS 
Inc, Chicago, IL) was used for all analyses.
Results
Characteristics of study sample  
and participation
A total of 210 women were initially invited to participate in 
the study and randomly assigned to one of three treatment 
groups, ie, 70 in Group A, 70 in Group B, and 70 in Group C. 
Table 1 geometric mean (± standard deviation) of baseline characteristics of participating women at time of enrolment (#20 weeks’ 
gestation) and delivery
Weeks of gestation Characteristic Group A Group B Group C P value
#20 Age ± sD 25.8 ± 4.9 24.3 ± 4.6 25.4 ± 5.4 0.21
BMi (17–19 weeks) ± sD 26.3 ± 4 26.1 ± 4.8 25.8 ± 4.3 0.75
Parity 0.76 0.65 0.77 0.5
nulliparity 33 (53.2%) 38 (55.1%) 33 (47.1%)
38
Weight gain (20–38 weeks) ± sD 3.2 ± 3.5 3.1 ± 1.3 3.4 ± 1.5 0.61
BMi ± sD 29.6 ± 3.5 29.3 ± 4.8 29.2 ± 4.3 0.61
Abbreviations: BMi, body mass index; sD, standard deviation.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Of these, four (1.9%) were excluded at 28 weeks and five 
(2.38%) at 38 weeks due to detection of exclusion criteria, 
leading to a total dropout rate of 4.28%. Two hundred and 
one remaining subjects (95.72%; 62 in Group A, 69 in Group 
B, and 70 in Group C) completed the study protocol, and 
had blood samples taken at baseline and at all assigned time 
points after supplementation (Figure 2). The participants 
were matched according to body mass index (P = 0.75), parity 
(P = 0.50), age (P = 0.21), baseline hemoglobin (P = 0.7), 
and ferritin levels (P = 0.37).
Withdrawals from the study before 36 weeks’ gestation 
were due to relocation (n = 2, Group A) noncompliance 
(n = 2, Group A and Group B), and hemoglobin ,11 g/dL at 
38 weeks (n = 3, Group A) and were therefore excluded from 
the study and treated appropriately. Two women withdrew on 
the recommendation of their physician.
The baseline characteristics of the participating women 
by treatment group are shown in Table 1. The women did 
not differ in any of the physiologic study variables (body 
mass index, age, parity, weight gain), or initial hemoglobin 
or ferritin concentrations.
The mean age of the participating women was 25.5 ± 5.04 
(range 19.7–30.7) years; 49.2% of the participants were 
aged 19–24 years, 27.7% were aged 25–29 years, and 23.1% 
were aged 30 years or older. More than 50% of participants 
(n = 104) were nulliparous at study entry. The average baseline 
hemoglobin and ferritin concentrations were 12.03 ± 0.79 g/dL 
and 14.16 ± 11.13 µg/L, respectively. The baseline range for 
hemoglobin concentration was 11.19–12.93 g/dL.
iron status and relative effectiveness  
of iron supplementation regimens
Table 2 summarizes the data comparing mean hemoglobin 
and serum ferritin levels for women who completed the study 
as measured at designated time points. Figures 2 and 3 show 
time point-correlated geometric mean values for hemoglobin. 
No significant difference was found between the treatment 
groups for hemoglobin levels at 28 weeks. At 38 weeks, the 
mean hemoglobin level in Group B was significantly lower 
than in Group A and Group C (P = 0.018), but the difference 
was of no clinical significance. The mean serum ferritin level 
increased significantly in Group C at 28 weeks’ gestation 
(P = 0.03). When comparing the final levels at 38 weeks, a 
significant difference was observed between Group B and 
the other two groups in this iron status indicator (P = 0.035). 
This difference was also of marginal clinical significance 
(19.9 µg/L in Group B).
Birth outcome
An overall comparison of average birth parameters for the 
three treatment groups is summarized in Table 3. Infants 
born to women who were assigned to the different treatment 
groups showed no significant difference in average birth 
weight (P = 0.521). The difference in pregnancy termina-
tion week was insignificant across the randomization groups 
(P = 0.13), as was the incidence of cesarean section births, 
preterm delivery, and low birth weight across the groups 
(P = 0.31, 0.25, and 0.33, respectively). Two babies (one 
in Group A and one in Group C) were of low birth weight, 
and eight babies (Group A, n = 4; Group B, n = 3; Group C, 
n = 1) were delivered preterm.
Adherence to regimen and side effects
Adherence to the regime was 100% according to data pro-
vided in the forms for the participants. No side effects were 
reported throughout the duration of the study.
Discussion
Low hemoglobin caused most commonly by iron deficiency is 
highly prevalent in pregnant women, and represents a global 
clinical problem with considerable impact on public health 
and health care systems.1 Various routine iron supplementa-
tion regimes have been proposed in recent decades to address 
this issue from the public health perspective, most commonly 
consisting of daily iron supplementation. Our data suggest 
that there is no significant benefit of daily iron supplemen-
tation over intermittent dosing regimes for maintenance of 
safe hematologic marker levels and for preventing pregnancy 
and neonatal complications in pregnant women who are 
nonanemic at #20 weeks. The absence of a placebo control 
group allows only a comparison between daily, twice-weekly, 
and once-weekly supplementation groups. However, given 
that it has been well established by various studies that daily 
antenatal iron supplementation increases hemoglobin levels 
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in maternal blood both antenatally and postnatally,17 that 
absence of iron supplementation during pregnancy increases 
the risk of anemia,18 and that various countries now recom-
mend routine iron supplementation as a conceptual part of 
their public health care policy (US, France,19 Iran), our goal 
was not to assess the impact of absence of iron supplemen-
tation in comparison with iron supplies, but to compare the 
effect of various iron supplementation regimens in a matched 
sample of pregnant women.
In the women who were nonanemic at 20#weeks’ 
gestation, weekly supplementation was less effective in 
preventing hemoglobin levels ,11 g/dL compared with 
twice-weekly and daily supplementation regimes. However, 
the twice-weekly regime has shown equal effectiveness as a 
daily supplementation regimen with respect to maintaining 
safe hemoglobin and ferritin levels throughout pregnancy. In 
addition to this, based on WHO criteria for the lowest (5th 
percentile) mid-pregnancy hemoglobin level of 10.5 g/dL,16 
also proposed by Milman et al,20 none of the women who were 
excluded due to hemoglobin levels ,11 g/dL at 28 weeks 
were in fact anemic (10.6, 10.7, and 10.7 g/dL). Moreover, 
this finding could be explained by the physiologic hemodilu-
tion that occurs during this stage of pregnancy. The reason 
they were transferred to a daily supplementation regimen was 
based on a cutoff point of 11 g/dL for anemia in pregnant 
women throughout pregnancy applied in routine Iranian 
clinical practice in accordance with the Iranian   Ministry of 
Health recommendation.
Although hemoglobin levels were significantly lower 
in Group B compared with Groups A and C (P = 0.018) at 
38 weeks, the difference was not clinically significant (Hb 
level .11 g/dL). A similar trend was observed for the differ-
ence in ferritin levels, in that although daily supplementation 
led to a significant increase in ferritin at 28 weeks (P = 0.03), 
this difference was not maintained towards 38 weeks in com-
parison with the other two regimes. Group B, on the other 
hand, achieved significantly lower ferritin levels compared 
with Group A and Group C at 38 weeks, but again this was 
not clinically significant.
Various studies comparing daily versus intermittent 
regimens have shown that the intermittent regimen is less 
effective in anemic pregnant women,21,22 while other studies 
conducted in anemic23 and nonanemic24 women demonstrate 
equal efficacy,25 frequently due to poor adherence to the 
regime in the daily supplementation setting. In addition 
to equal ability to maintain safe hematologic markers on 
both regimes, studies also report a possible adverse effect 
of hemoconcentration on birth outcome24 and other aspects 
associated with daily exposure to iron, such as hypertension, 
in healthy nonanemic women.26
At 38 weeks, 15.7% women in Group C had hemoconcen-
tration, compared with 8.1% and 7.3% in Group A and Group 
B, respectively. However, the initial hemoglobin levels were 
higher in Group C (12.9% had hemoconcentration at week 
20 compared with 5.3% in Group B), which may account for 
the considerably higher percentage of women with hemocon-
centration in this group at the time of delivery.
It is noteworthy that many studies comparing daily versus 
intermittent iron supplementation attribute the low effective-
ness of routine daily administration to low adherence with 
the daily regimen,21,27 which is mainly due to the side effects 
of daily iron supplementation. Given the fact that all women 
in our study reported full adherence and no side effects, 
it may be important to study the social characteristics of   
target study populations to verify this finding.
Table 2 effect of once-weekly, twice-weekly, and daily iron supplementation on hemoglobin and ferritin levels in nonanemic 
pregnant women
Weeks of  
gestation
Group A (n = 62) Group B (n = 69) Group C (n = 70)
Hemoglobin Ferritin Hemoglobin Ferritin Hemoglobin Ferritin
20 12.1 ± 0.81   13.4 ± 9.6 11.9 ± 0.69 13.5 ± 10.1 12.06 ± 0.87 15.8 ± 13
28 11.9 ± 0.82 16.09 ± 9.8 11.9 ± 0.75 14.2 ± 9.1   12.1 ± 0.83 18.8 ± 12.1*
38 12.4 ± 0.85   21.3 ± 11.07 12.1 ± 0.78* 19.9 ± 11.2*   12.5 ± 0.93 25.3 ± 13.2
Note: *Statistically significant.
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Another aspect that may have played a role in the sig-
nificantly high adherence during this study is that all women 
were informed in detail about the general effects and benefits 
of iron on the course of their pregnancy and its outcome, 
and were clearly instructed on how and when to take their 
tablet(s). This is in accordance with another compliance 
study demonstrating that this approach increases compli-
ance rates.27
The dietary habits of the study sample were not specifi-
cally recorded, but given the relative ethnic, religious, and 
socioeconomic homogeneity of the participating women, it 
may be reasonably assumed that there were no significant dif-
ferences in their diet. None of the participating women were 
vegetarians, and all were informed regarding proper dietary 
composition during pregnancy. In accordance with Islamic 
law, which does not allow pregnant women to fast, none 
were fasting. Several studies have demonstrated that anemia 
in pregnancy is associated with a risk of low birth weight 
or premature delivery.28–30 Our study shows that low birth 
weight occurred with equal frequency in the daily and weekly 
supplementation groups (n = 1 in each group), while no low 
birth weight infants occurred in the twice-weekly group.
Pan-population approaches using global routine iron 
supplementation, although introduced, eg, in India in the early 
70s,21 have proven to be ineffective in reducing the prevalence 
of anemia during pregnancy. Moreover, such approaches 
may not be safe in all circumstances, as shown by studies 
demonstrating an adverse effect on pregnancy outcome in 
women with higher hemoglobin levels who receive iron 
supplementation. Currently there is no general solution for 
this worldwide problem, which rather emphasizes the need for 
careful evaluation of target populations with respect to social, 
dietary, and religious customs, and in particular the need for 
an individual approach in each pregnant woman. Rigid iron 
supplementation rules based on inaccurate generalizations 
from studies conducted in different global and political regions 
in different ethnic populations and sometimes in a different 
decade may eventually cause harm instead of benefit in a 
subset of pregnant women and their babies.
In conclusion, our study shows that assessment of hema-
tologic parameters in early pregnancy should be routinely 
incorporated into prenatal care and, based on this evaluation, 
appropriate iron supplementation should be proposed for 
every woman, regardless of location or background. This 
regimen should be in accordance with local and national 
population health and the woman’s individual medical his-
tory and needs. From a more general perspective, a heated 
debate concerning daily versus intermittent iron supplemen-
tation has developed in recent years. Both approaches have 
been corroborated with clinical trials, yet no clear conclu-
sion can be reached. Although our results do not provide a 
definite answer, they do suggest that, in nonanemic women, 
a twice-weekly iron supplementation regime may represent 
a reasonable compromise for an initial iron dosing regimen 
in nonpregnant women that may be adjusted in concordance 
with the development of iron markers during pregnancy.
Acknowledgment
We would like to thank the Student Research Committee, 
Urmia University of Medical Sciences, for their support of 
this research.
Disclosure
The authors report no conflicts of interest in this work.
Reference
1.  Stoltzfus R. Defining iron-deficiency anemia in public health terms: 
a time for reflection. J Nutr. 2001;131(2S–2):565S–567S.
2.  Sloan NL, Jordan E, Winikoff B. Effects of iron supplementation 
on maternal hematologic status in pregnancy. Am J Public Health. 
2002;92(2):288–293.
3.  Lozoff B, Georgieff MK. Iron deficiency and brain development. Semin 
Pediatr Neurol. 2006;13(3):158–165.
4.  Haram K, Nilsen ST, Ulvik RJ. Iron supplementation in preg-
nancy – evidence and controversies. Acta Obstet Gynecol Scand. 
2001;80(8):683–688.
5.  Milman N. Iron prophylaxis in pregnancy – general or individual and in 
which dose? Ann Hematol. 2006;85(12):821–828.
6.  LeBlanc CP, Fiset S, Surette ME, Turgeon O’Brien H, Rioux FM. 
Maternal iron deficiency alters essential fatty acid and eicosanoid 
metabolism and increases locomotion in adult guinea pig offspring. J Nutr. 
2009;139(9):1653–1659.
Table 3 Pregnancy outcome analysis in randomization groups
Variable Group A Group B Group C P value
Birth weight 3212 ± 461.4 3222.38 ± 500 3274.26 ± 408.3 0.7 F = 0.35
Pregnancy termination week 39.9 ± 1.2 39.5 ± 1.4 40.03 ± 1.6 0.12 F = 2.1
C/s 14 (20.9%) 22 (31.9%) 21 (30.9%) 0.29
Preterm delivery 4 (7.5%) 3 (5.8%) 1 (1.4%) 0.25
LBW 1 (1.5%) 0 (0%) 1 (1.4%) 0.61
Abbreviations: LBW, low birth weight; C/s, cesarean section.Therapeutics and Clinical Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/therapeutics-and-clinical-risk-management-journal
Therapeutics and Clinical Risk Management is an international, peer-
reviewed journal of clinical therapeutics and risk management, focusing 
on concise rapid reporting of clinical studies in all therapeutic areas, 
outcomes, safety, and programs for the effective, safe, and sustained 
use of medicines. This journal is indexed on PubMed Central, CAS, 
EMBase, Scopus and the Elsevier Bibliographic databases. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
428
Yekta et al
  7.  Andrews NC. Iron homeostasis: insights from genetics and animal 
models. Nat Rev Genet. 2000;1(3):208–217.
  8.  Hematologic disorders of pregnancy. 3rd ed. In: Fortner KB, 
Szymanski L, Fox HE, Wallach EE, editors. The Johns Hopkins Manual 
of Gynecology and Obstetrics. 3rd ed. Philadelphia, PA: Lippincott 
Williams and Wilkins; 2007:215–230.
  9.  DeMaeyer EM, Dallman P, Gurney JM, Hallberg L, Sood SK, 
  Srikantia SG. Preventing and controlling iron deficiency anaemia through 
primary health care. Geneva: World Health Organization; 1989.
  10.  Beard JL. Effectiveness and strategies of iron supplementation during 
pregnancy. Am J Clin Nutr. 2000;71(5 Suppl):1288S–1294S.
  11.  Yekta Z, Ayatollahi H, Pourali R, Farzin A. Predicting factors in iron 
supplement intake among pregnant women in urban care setting. JRHS. 
2008;8(1).
  12.  Beard JL. Weekly iron intervention: the case for intermittent iron 
supplementation. Am J Clin Nutr. 1998;68(2):209–212.
  13.  Hahn PF, Bale WF, Ross JF, Balfour WM, Whipple GH. Radioactive 
iron absorption by gastro-intestinal tract: influence of anemia, anoxia, 
and antecedent feeding distribution in growing dogs. J Exp Med. 
1943;78(3):169–188.
  14.  Wright AJ, Southon S. The effectiveness of various iron-supplemen-
tation regimens in improving the Fe status of anaemic rats. Br J Nutr. 
1990;63(3):579–585.
  15.  Viteri FE, Liu X, Tolomei K, Martin A. True absorption and retention 
of supplemental iron is more efficient when iron is administered every 
three days rather than daily to iron-normal and iron-deficient rats. J Nutr. 
1995;125(1):82–91.
  16.  Prevention and management of severe anaemia in pregnancy. Report 
of a Technical Working Group, Geneva, Switzerland: World Health 
Organisation; 1993.
  17.  Pena-Rosas JP, Viteri FE. Effects of routine oral iron supplementation 
with or without folic acid for women during pregnancy. Cochrane 
Database Syst Rev. 2006;3:CD004736.
  18.  Preziosi P, Prual A, Galan P, Daouda H, Boureima H, Hercberg S. 
Effect of iron supplementation on the iron status of pregnant women: 
consequences for newborns. Am J Clin Nutr. 1997;66(5):1178–1182.
  19.  Makrides M, Crowther CA, Gibson RA, Gibson RS, Skeaff CM.   Efficacy 
and tolerability of low-dose iron supplements during pregnancy: a ran-
domized controlled trial. Am J Clin Nutr. 2003;78(1):145–153.
  20.  Milman N, Byg KE, Agger AO. Hemoglobin and erythrocyte indi-
ces during normal pregnancy and postpartum in 206 women with 
and without iron supplementation. Acta Obstet Gynecol Scand. 
2000;79(2):89–98.
  21.  Mukhopadhyay A, Bhatla N, Kriplani A, Pandey RM, Saxena R. 
Daily versus intermittent iron supplementation in pregnant women: 
hematological and pregnancy outcome. J Obstet Gynaecol Res. 
2004;30(6):409–417.
  22.  Mumtaz Z, Shahab S, Butt N, Rab MA, DeMuynck A. Daily iron supple-
mentation is more effective than twice weekly iron supplementation in 
pregnant women in Pakistan in a randomized double-blind clinical trial. 
J Nutr. 2000;130(11):2697–2702.
  23.  Young MW, Lupafya E, Kapenda E, Bobrow EA. The effectiveness 
of weekly iron supplementation in pregnant women of rural northern 
Malawi. Trop Doct. 2000;30(2):84–88.
  24.  Casanueva E, Viteri FE, Mares-Galindo M, et al. Weekly iron as a safe 
alternative to daily supplementation for nonanemic pregnant women. 
Arch Med Res. 2006;37(5):674–682.
  25.  Ridwan E, Schultink W, Dillon D, Gross R. Effects of weekly iron 
supplementation on pregnant Indonesian women are similar to those 
of daily supplementation. Am J Clin Nutr. 1996;63(6):884–890.
  26.  Ziaei S, Norrozi M, Faghihzadeh S, Jafarbegloo E. A randomised 
placebo-controlled trial to determine the effect of iron supplemen-
tation on pregnancy outcome in pregnant women with haemoglo-
bin . or = 13.2 g/dl. BJOG. 2007;114(6):684–688.
  27.  Habib F, Alabdin EH, Alenazy M, Nooh R. Compliance to iron 
supplementation during pregnancy. J Obstet Gynaecol. 2009;29(6): 
487–492.
  28.  Kidanto HL, Mogren I, Lindmark G, Massawe S, Nystrom L. Risks for 
preterm delivery and low birth weight are independently increased by 
severity of maternal anaemia. S Afr Med J. 2009;99(2):98–102.
  29.  Lone FW, Qureshi RN, Emmanuel F. Maternal anaemia and its impact on 
perinatal outcome in a tertiary care hospital in Pakistan. East Mediterr 
Health J. 2004;10(6):801–807.
  30.  Scanlon KS, Yip R, Schieve LA, Cogswell ME. High and low hemo-
globin levels during pregnancy: differential risks for preterm birth 
and small for gestational age. Obstet Gynecol. 2000;96(5 Pt 1): 
741–748.